Download PDF
CC BY 4.0 · Pharmaceutical Fronts 2020; 02(01): e23-e27
DOI: 10.1055/s-0040-1708511
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Establishment and Application of Engineered NIH 3T3 Cell Line with Stable Human RAGE Expression

Xinyi Xiao
1   Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Jiao Tong University College of Pharmacy, Ministry of Education, Shanghai, People's Republic of China
,
Hui Chen
1   Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Jiao Tong University College of Pharmacy, Ministry of Education, Shanghai, People's Republic of China
,
Pameila Paerhati
1   Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Jiao Tong University College of Pharmacy, Ministry of Education, Shanghai, People's Republic of China
,
Meiqi Zhou
1   Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Jiao Tong University College of Pharmacy, Ministry of Education, Shanghai, People's Republic of China
,
Zhuoyi Yang
1   Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Jiao Tong University College of Pharmacy, Ministry of Education, Shanghai, People's Republic of China
,
Siyi Bai
1   Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Jiao Tong University College of Pharmacy, Ministry of Education, Shanghai, People's Republic of China
,
Yunsheng Yuan
1   Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Jiao Tong University College of Pharmacy, Ministry of Education, Shanghai, People's Republic of China
› Author Affiliations Funding This research work was supported by the National Natural Science Foundation of China (31671388 and 81302825), the National Science and Technology Major Project “Key New Drug Creation and Manufacturing Program” (2019ZX09201001), and the Shanghai Jiao Tong University Medical–Engineering Joint Project (YG2019QNA50).
Further Information

Publication History

Publication Date:
21 March 2020 (online)

Also available at
   Permissions and Reprints

Corrected by:

Erratum to: Establishment and Application of Engineered NIH 3T3 Cell Line with Stable Human RAGE ExpressionPharmaceutical Fronts 2020; 02(01): e77-e77
DOI: 10.1055/s-0040-1710004

Abstract

Aim NIH3T3 cell line with expression of human receptor for advanced glycation end-products (hRAGE) transduced with lentivirus vectors was used to analyze affinity, biological activity, and/or molecular mechanisms of molecules targeting the hRAGE pathway.

Method The DNA fragment coding for hRAGE gene was integrated into the genome of NIH3T3 cells using lentivirus transduction. Cells expressing hRAGE were selected with puromycin, and the level of hRAGE expression was analyzed by Western blot. To establish a stable cell line, colonies of hRAGE-expressing cells were generated, and the level of RAGE expression in each engineered cell line was analyzed within 20 generations. Flow cytometry assay was used to verify affinity of anti-hRAGE antibody binding to hRAGE on the surface of engineered cells. The engineered NIH3T3 cell line was applied to assess effects of anti-hRAGE blocking antibody on amyloid β-induced cells apoptosis by CCK-8 assay.

Results The engineered NIH3T3 cell line (hRAGE-NIH3T3) could stably express human RAGE. Commercial anti-RAGE polyclonal antibody could recognize and bind to human RAGE on the surface of hRAGE-NIH3T3 but not original NIH3T3 cells. In addition, hRAGE-NIH3T3 was more sensitive to RAGE pathway-dependent stimulation. Our data show that the hRAGE-NIH3T3 cell line established is an excellent tool in the study of RAGE-targeting molecules based on the cellular level, biological function, and RAGE-mediated molecular mechanisms.

Keywords

RAGE - engineered cell line - lentiviral - transduction - flow cytometry
 

  • Reference

  • 1 Rouhiainen A, Kuja-Panula J, Tumova S, Rauvala H. RAGE-mediated cell signaling. Methods Mol Biol 2013; 963: 239-263
    PubMedSearch in Google Scholar
  • 2 Fritz G. RAGE: a single receptor fits multiple ligands. Trends Biochem Sci 2011; 36 (12) 625-632
    CrossrefPubMedSearch in Google Scholar
  • 3 Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) 2010; 2 (04) 1184-1195
    Search in Google Scholar
  • 4 Han SH, Kim YH, Mook-Jung I. RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells 2011; 31 (02) 91-97
    CrossrefPubMedSearch in Google Scholar
  • 5 Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274 (28) 19919-19924
    CrossrefPubMedSearch in Google Scholar
  • 6 Fages C, Nolo R, Huttunen HJ, Eskelinen E, Rauvala H. Regulation of cell migration by amphoterin. J Cell Sci 2000; 113 (Pt 4): 611-620
    PubMedSearch in Google Scholar
  • 7 Yan SD, Chen X, Fu J. , et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382 (6593): 685-691
    CrossrefPubMedSearch in Google Scholar
  • 8 Hofmann MA, Drury S, Fu C. , et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97 (07) 889-901
    CrossrefPubMedSearch in Google Scholar
  • 9 Ray R, Juranek JK, Rai V. RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyotrophic lateral sclerosis. Neurosci Biobehav Rev 2016; 62: 48-55
    CrossrefPubMedSearch in Google Scholar
  • 10 Deane R, Singh I, Sagare AP. , et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 2012; 122 (04) 1377-1392
    CrossrefPubMedSearch in Google Scholar
  • 11 Li Y, Wu R, Tian Y. , et al. RAGE/NF-κB signaling mediates lipopolysaccharide induced acute lung injury in neonate rat model. Int J Clin Exp Med 2015; 8 (08) 13371-13376
    PubMedSearch in Google Scholar
  • 12 Liu Y, Liang C, Liu X. , et al. AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-kappaB pathways. Atherosclerosis 2010; 208 (01) 34-42
    CrossrefPubMedSearch in Google Scholar
  • 13 Yeh CH, Sturgis L, Haidacher J. , et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001; 50 (06) 1495-1504
    CrossrefPubMedSearch in Google Scholar
  • 14 Bianchi R, Giambanco I, Donato R. S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 Co-regulation of COX-2 expression by S100B, IL-1beta and TNF-alpha. Neurobiol Aging 2010; 31 (04) 665-677
    CrossrefPubMedSearch in Google Scholar
  • 15 Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007; 8 (01) 49-62
    CrossrefPubMedSearch in Google Scholar
  • 16 Tanji N, Markowitz GS, Fu C. , et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11 (09) 1656-1666
    PubMedSearch in Google Scholar
  • 17 Wendt T, Harja E, Bucciarelli L. , et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006; 185 (01) 70-77
    CrossrefPubMedSearch in Google Scholar
  • 18 Onyeagucha BC, Mercado-Pimentel ME, Hutchison J, Flemington EK, Nelson MA. S100P/RAGE signaling regulates microRNA-155 expression via AP-1 activation in colon cancer. Exp Cell Res 2013; 319 (13) 2081-2090
    CrossrefPubMedSearch in Google Scholar
  • 19 Tesarova P, Cabinakova M, Mikulova V, Zima T, Kalousova M. RAGE and its ligands in cancer - culprits, biomarkers, or therapeutic targets?. Neoplasma 2015; 62 (03) 353-364
    CrossrefPubMedSearch in Google Scholar
  • 20 Xia P, He H, Kristine MS. , et al. Therapeutic effects of recombinant human S100A6 and soluble receptor for advanced glycation end products(sRAGE) on CCl4-induced liver fibrosis in mice. Eur J Pharmacol 2018; 833: 86-93
    CrossrefPubMedSearch in Google Scholar
  • 21 Pontén F, Jirström K, Uhlen M. The Human Protein Atlas--a tool for pathology. J Pathol 2008; 216 (04) 387-393
    CrossrefPubMedSearch in Google Scholar
  • 22 Shafaghat F, Abbasi-Kenarsari H, Majidi J, Movassaghpour AA, Shanehbandi D, Kazemi T. preparation of proper immunogen by cloning and stable expression of cDNA coding for human hematopoietic stem cell marker CD34 in NIH-3T3 mouse fibroblast cell line. Adv Pharm Bull 2015; 5 (01) 69-75
    PubMedSearch in Google Scholar
  • 23 Salehi-Lalemarzi H, Shanehbandi D, Shafaghat F. , et al. Cloning and stable expression of cDNA coding for platelet endothelial cell adhesion molecule-1 (PECAM-1, CD31) in NIH-3T3 cell line. Adv Pharm Bull 2015; 5 (02) 247-253
    CrossrefPubMedSearch in Google Scholar
  • 24 Abbasi-Kenarsari H, Shafaghat F, Baradaran B, Movassaghpour AA, Shanehbandi D, Kazemi T. Cloning and expression of CD19, a human B-cell marker in NIH-3T3 cell line. Avicenna J Med Biotechnol 2015; 7 (01) 39-44
    PubMedSearch in Google Scholar
  • 25 Weng S, Zhou L, Deng Q. , et al. Niclosamide induced cell apoptosis via upregulation of ATF3 and activation of PERK in Hepatocellular carcinoma cells. BMC Gastroenterol 2016; 16: 25
    CrossrefPubMedSearch in Google Scholar
  • 26 Hudson BI, Carter AM, Harja E. , et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J 2008; 22 (05) 1572-1580
    CrossrefPubMedSearch in Google Scholar
  • 27 Liu Z, O'Rourke J. Expediting antibody discovery with a cell and bead multiplexed competition assay. SLAS Discov 2018; 23 (07) 667-675
    PubMedSearch in Google Scholar
  • 28 Elgundi Z, Reslan M, Cruz E, Sifniotis V, Kayser V. The state-of-play and future of antibody therapeutics. Adv Drug Deliv Rev 2017; 122: 2-19
    CrossrefPubMedSearch in Google Scholar
  • 29 Kim Y, Mook-Jung I. PRAK mediates Aβ-RAGE driven autophagy pathway. Oncotarget 2017; 8 (04) 5648-5649
    CrossrefPubMedSearch in Google Scholar
  • 30 Oczypok EA, Perkins TN, Oury TD. All the “RAGE” in lung disease: the receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses. Paediatr Respir Rev 2017; 23: 40-49
    PubMedSearch in Google Scholar
  • 31 Litwinoff E, Hurtado Del Pozo C, Ramasamy R, Schmidt AM. Emerging targets for therapeutic development in diabetes and its complications: the RAGE signaling pathway. Clin Pharmacol Ther 2015; 98 (02) 135-144
    Search in Google Scholar
  • 32 Sakuma T, Barry MA, Ikeda Y. Lentiviral vectors: basic to translational. Biochem J 2012; 443 (03) 603-618
    CrossrefPubMedSearch in Google Scholar
  • 33 Milone MC, O'Doherty U. Clinical use of lentiviral vectors. Leukemia 2018; 32 (07) 1529-1541
    CrossrefPubMedSearch in Google Scholar